评论
打印
Doctors push back on the ‘right to try’ experimental treatments
医生们纷纷推迟“尝试实验药物的权利”相关治疗
By Alexandra Sifferlin
作者：Alexandra Sifferlin
NO ONE WANTS TO ARGUE AGAINST GIVING potentially beneficial drugs to people who need them.
没有人会反对向有需要的人群提供可能有益的药物这一做法。
But not everyone in the medical community is convinced that a national “right to try” policy,
然而，医学界并非所有人都相信，“尝试实验药物的权利”这一国家政策，
which would allow people with fatal illnesses to have access to drugs not yet approved by federal authorities, will make life better for patients.
该政策让身患绝症的人有了使用尚未获得联邦当局批准的药物的机会，真的能给患者的生活带来改善。
Such laws have already passed in dozens of states,
数十个州都已经通过了这些法律，
and the Senate passed a version of the federal bill in August.
参议院8月份也通过了相关的联邦法案。
Now, as the House of Representatives weighs a bill on the matter—
如今，因为下议院还在就此事权衡一个法案——
a proposal that President Donald Trump lauded in his Jan.30 State of the Union address—
特朗普1月30日发表国情咨文演讲时曾经公开称赞过该提案——
doctors and medical ethicists are sounding an alarm.
医生和医学伦理学家便纷纷敲响了警钟。
For a drug to be approved for use in the U.S.,
美国的药物要通过批准投入使用，
it must undergo several rounds of clinical testing.
得经过数轮的临床试验。
The U.S. Food and Drug Administration (FDA)—the agency that oversees that approval process—
但美国食品和药物管理局（FDA） - 监督批准程序的机构 -
does have a system in place for getting unapproved drugs to people who need them,
的确有相关的机制给有需要的患者提供尚未批准的药物，
often referred to as compassionate use or expanded access.
这一机制通常被称之为“同情用药”或“扩大使用”。
译文由可可原创，仅供学习交流使用，未经许可请勿转载。
